Chongqing Carelife Pharmaceutical

Chongqing Carelife Pharmaceutical is a specialized pharmaceutical company based in China, focusing on the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. As a core subsidiary of the publicly traded Chongqing Pharscin Pharmaceutical, the company operates state-of-the-art, GMP-compliant facilities that serve both domestic and international markets. Their product portfolio is primarily centered on small molecule therapeutics for cardiovascular diseases, metabolic disorders, and gastrointestinal conditions. Key commercial offerings include widely used generic medications such as atorvastatin, rosuvastatin, and various dipeptidyl peptidase 4 inhibitors. By integrating chemical synthesis with advanced formulation capabilities, Chongqing Carelife Pharmaceutical maintains a competitive position in the global generic supply chain. The company continues to expand its pipeline through rigorous R&D aimed at high-barrier generic drugs and innovative chemical entities.